GHO Capital has acquired drug development services provider Quotient Clinical from Bridgepoint Development Capital. Quotient reportedly had an enterprise value of £165 million. The company’s Translational Pharmaceutics platform integrates formulation development, real-time GMP manufacturing and clinical testing. BDC had acquired Quotient in 2013; the firm is said to have generated a 6.4x return from the sale. HSBC Bank provided debt financing for the transaction.